Ertapenem

C. diff Risk

Medium

Oral Bioavailability

NA

Approximate Cost

Dosing

1g IV q24h

500 mg q24h
CrCl Less Than 30 mL/min

1 g q24h
CrCl Greater Than 30 mL/min

General Information

Common Usage

Targeted therapy of ESBL infections and other resistant gram negative infections.

Empiric therapy when broad spectrum of carbapenems is desired without the need for anti-pseudomonal activity.

Adverse Effects

  • Immediate and delayed-type allergy

  • GI disturbance

  • Cytopenias, eosinophilia, positive Coombs

  • Liver enzyme abnormalities

  • Seizure risk lower than other carbapenems

Pharmacology

Antimicrobial class: Carbapenem

Pregnancy category: B

Average serum half life: 4 hours

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Biliary penetration: Moderate